Study to Determine if Pre- and Post- Operative TAP Catheters With Ropivacaine Versus Placebo Affects Anesthetic, Narcotic Dosing, and Pain Scores (TAP RCT)
Primary Purpose
Pain, Postoperative, Delirium, Anesthesia, Local
Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ropivacaine HCL
sodium chloride
Sponsored by
About this trial
This is an interventional prevention trial for Pain, Postoperative
Eligibility Criteria
Inclusion Criteria:
- Age >=50 years.
- Subjects will be undergoing an elective intra-abdominal or abdominal wall operation, including pelvic operations. Surgery specialties included are general surgery, surgical oncology, urology, gynecology, plastic surgery.
Exclusion Criteria:
- Subjects with a history of dementia or aphasia, as visual analog scale and confusion assessment will be unreliable.
- Patients with an epidural or spinal catheter block.
- Patients who do not speak English so that a language barrier is not confused with VAS scoring or confusion.
- Patients who are abusing alcohol defined by a high AUDIT score (>8) will be excluded.
- History of bipolar disorder or a psychotic disorder (such as a psychotic major depression, schizophrenia, schizoaffective disorder, or psychosis in Alzheimer's disease or other dementia).
- Patients with a documented allergy to ropivacaine or other sodium channel blockers.
Sites / Locations
- Denver Veterans Affairs Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Ropivacaine
Placebo
Arm Description
Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
Outcomes
Primary Outcome Measures
Pain Scores
Pain scores from the visual analog scale
Secondary Outcome Measures
Amount of anesthetic
MAC of inhalational agent, or total amount of IV anesthetic used during the operation
Amount of narcotic administered postoperatively
Amount of morphine equivalents per day measured after the operation
Full Information
NCT ID
NCT03149783
First Posted
March 10, 2017
Last Updated
May 26, 2021
Sponsor
University of Colorado, Denver
1. Study Identification
Unique Protocol Identification Number
NCT03149783
Brief Title
Study to Determine if Pre- and Post- Operative TAP Catheters With Ropivacaine Versus Placebo Affects Anesthetic, Narcotic Dosing, and Pain Scores
Acronym
TAP RCT
Official Title
A Randomized Controlled Trial to Determine if Pre- and Post- Operative Regional Pain Control (Transversus Abdominis Plane Block) With Ropivacaine Versus Placebo Leads to Lower Anesthetic and Narcotic Dosing, and Alters Pain Scores
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
February 13, 2018 (Actual)
Primary Completion Date
August 31, 2021 (Anticipated)
Study Completion Date
October 31, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A randomized controlled trial to determine if pre- and post- operative regional pain control (transversus abdominis plane block) with ropivacaine versus placebo leads to lower anesthetic and narcotic dosing, and alters pain scores.
This study plans to learn more about regional anesthesia and pain control during abdominal surgery. The study will gather data about the effectiveness of continuous catheter infusion of local anesthetic after an abdominal operation. Outcomes include pain scores, IV pain medicine requirements, and delirium.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Delirium, Anesthesia, Local
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized Controlled Double Blind Trial
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
"Study drug" label of drug
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Ropivacaine
Arm Type
Experimental
Arm Description
Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
Intervention Type
Drug
Intervention Name(s)
Ropivacaine HCL
Intervention Description
Ropivacaine injected after placement of catheters, then infused during the operation
Intervention Type
Drug
Intervention Name(s)
sodium chloride
Other Intervention Name(s)
saline
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Pain Scores
Description
Pain scores from the visual analog scale
Time Frame
Days 0-7 following the operation
Secondary Outcome Measure Information:
Title
Amount of anesthetic
Description
MAC of inhalational agent, or total amount of IV anesthetic used during the operation
Time Frame
During the operation
Title
Amount of narcotic administered postoperatively
Description
Amount of morphine equivalents per day measured after the operation
Time Frame
Days 0-7 postop
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age >=50 years.
Subjects will be undergoing an elective intra-abdominal or abdominal wall operation, including pelvic operations. Surgery specialties included are general surgery, surgical oncology, urology, gynecology, plastic surgery.
Exclusion Criteria:
Subjects with a history of dementia or aphasia, as visual analog scale and confusion assessment will be unreliable.
Patients with an epidural or spinal catheter block.
Patients who do not speak English so that a language barrier is not confused with VAS scoring or confusion.
Patients who are abusing alcohol defined by a high AUDIT score (>8) will be excluded.
History of bipolar disorder or a psychotic disorder (such as a psychotic major depression, schizophrenia, schizoaffective disorder, or psychosis in Alzheimer's disease or other dementia).
Patients with a documented allergy to ropivacaine or other sodium channel blockers.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Douglas Overbey, MD
Phone
573-225-7728
Email
douglas.overbey@ucdenver.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Robinson, MD
Phone
303-399-8020 Ext. 2952
Email
thomas.robinson@ucdenver.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Robinson, MD
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
Denver Veterans Affairs Medical Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80221
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Robinson, MD
Phone
303-399-8020
Ext
2952
Email
thomas.robinson@ucdenver.edu
First Name & Middle Initial & Last Name & Degree
Douglas Overbey, MD
Phone
573-225-7728
Email
douglas.overbey@ucdenver.edu
First Name & Middle Initial & Last Name & Degree
Thomas N Robinson, MD
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
No sharing
Learn more about this trial
Study to Determine if Pre- and Post- Operative TAP Catheters With Ropivacaine Versus Placebo Affects Anesthetic, Narcotic Dosing, and Pain Scores
We'll reach out to this number within 24 hrs